Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Japan’s Takeda Sheds Jobs In U.S., Europe
by Michael McCoy
January 23, 2012
| A version of this story appeared in
Volume 90, Issue 4
Following its September 2011 acquisition of the Swiss drugmaker Nycomed, Takeda Pharmaceutical is embarking on a restructuring program that will cut 2,800 jobs, or 9% of its workforce, across R&D, commercial, operations, and administrative functions. About 2,100 of the jobs to be eliminated are in Europe, and the balance are in the U.S. The Japanese company says it will also consolidate R&D and other sites across the globe. Takeda expects the plan to cost more than $900 million through 2015 but save $2.6 billion.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter